Portal de Periódicos da CAPES

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

2020; American Association for the Advancement of Science; Volume: 370; Issue: 6521 Linguagem: Inglês

10.1126/science.abd7728

1095-9203

Ania Wajnberg, Fatima Amanat, Adolfo Firpo, Deena R. Altman, Mark Bailey, Mayce Mansour, Meagan McMahon, Philip Meade, Damodara Rao Mendu, Kimberly A. Muellers, Daniel Stadlbauer, Kimberly Stone, Shirin Strohmeier, Viviana Simon, Judith A. Aberg, David L. Reich, Florian Krammer, Carlos Cordon‐Cardo,

Monoclonal and Polyclonal Antibodies Research

SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227